BioCentury
ARTICLE | Company News

Medivation, Astellas sales and marketing update

April 27, 2015 7:00 AM UTC

Germany’s Institute for Quality and Efficiency in Healthcare (IQWiG) said in an assessment that Xtandi enzalutamide from Astellas has “major” added benefit over “watchful waiting” in men ages 75 and ...